Drugs / SGI-1776
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01239108 | Oct 2010 → Apr 2012 | leukemia | Astex Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT00848601 | Feb 2009 → Oct 2010 | non-Hodgkin lymphoma, prostate cancer | Astex Pharmaceuticals, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2010-11-10 | Astex Pharmaceuticals, Inc. | Results SuperGen Discontinues Clinical Development of SGI-1776 astx.com ↗
SuperGen, Inc. (NASDAQ:SUPG) today announced that it has discontinued clinical development of its phase 1 PIM kinase drug candidate, SGI-1776, while continuing development of the PIM inhibitor program. |
| 2009-04-21 | Astex Pharmaceuticals, Inc. | Results SuperGen Presents PIM kinase inhibitor SGI-1776 at American Association for Cancer Research Annual Meeting astx.com ↗
SGI-1776 inhibited tumor growth significantly more effectively in xenograph models than administration of standard of care agents cytarabine and daunorubicin. |
| 2008-12-08 | Astex Pharmaceuticals, Inc. | Results SuperGen’s PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia astx.com ↗
SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that its oral PIM kinase inhibitor, SGI -1776, is effective both in vitro and in vivo in preclinical models of acute lymphoblastic leukemia (ALL) (Abstract #1922). |
| 2008-11-20 | Astex Pharmaceuticals, Inc. | Regulatory SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor astx.com ↗
SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that it has received clearance to initiate clinical trials with SGI-1776, an inhibitor of Pim kinases. |
| 2008-06-13 | Astex Pharmaceuticals, Inc. | Results SuperGen’s PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models astx.com ↗
Most notably, SGI -1776 induced significant tumor regression in MOLM -13 and MV-4-11 (AML) xenograft models. |
| 2008-04-16 | Astex Pharmaceuticals, Inc. | Results SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, that Causes Tumor Regression in AML Xenograft Models astx.com ↗
Most notably, SGI -1776 induced significant tumor regression in MV -4-11 (AML) and MOLM-13 (AML) xenograft models. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2010-11-10 | Astex Pharmaceuticals, Inc. | SuperGen Discontinues Clinical Development of SGI-1776 astx.com ↗ |
| 2009-04-21 | Astex Pharmaceuticals, Inc. | SuperGen Presents PIM kinase inhibitor SGI-1776 at American Association for Cancer Research Annual Meeting astx.com ↗ |
| 2008-12-08 | Astex Pharmaceuticals, Inc. | SuperGen’s PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia astx.com ↗ |
| 2008-11-20 | Astex Pharmaceuticals, Inc. | SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor astx.com ↗ |
| 2008-06-13 | Astex Pharmaceuticals, Inc. | SuperGen’s PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models astx.com ↗ |
| 2008-04-16 | Astex Pharmaceuticals, Inc. | SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, that Causes Tumor Regression in AML Xenograft Models astx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGI-1776 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01239108 ↗ |
| Action | Inhibit | “SGI-1776, a PIM Kinase Inhibitor” NCT00848601 ↗ |
| Modality | Small molecule | — CHEMBL1952329 ↗ |
| Route | Oral | “SGI-1776 will be administered orally” NCT01239108 ↗ |